
Commentary|Videos|December 17, 2025
Response Rates with Pumitamig Plus Chemo Suggest Synergistic Effect
Author(s)Peter Schmid, MD, PhD
Fact checked by: Paige Britt
A promising trial reveals pumitamig combined with chemotherapy shows high response rates, suggesting potential benefits for advanced cancer treatments.
Advertisement
Watch the first part of our interview with Peter Schmid, MD, PhD,
In the second part of our interview with Schmid, Barts Cancer Institute, London, England, he details the safety and efficacy results of pumitamig plus chemotherapy in patients with triple negative breast cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















